— Know what they know.
Not Investment Advice

MLTX NASDAQ

MoonLake Immunotherapeutics
1W: -7.4% 1M: -1.0% 3M: -6.2% YTD: +42.7% 1Y: -56.5% 3Y: -36.3% 5Y: +71.0%
$17.05
+0.68 (+4.15%)
 
Weekly Expected Move ±8.1%
$15 $16 $18 $19 $20
NASDAQ · Healthcare · Biotechnology · Alpha Radar Sell · Power 31 · $1.3B mcap · 65M float · 1.66% daily turnover · Short 30% of daily vol
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$1.3B
52W Range5.95-62.75
Volume573,908
Avg Volume1,079,188
Beta1.01
Dividend
Analyst Ratings
14 Buy 2 Hold 2 Sell
Consensus Buy
Company Info
CEOJorge Santos da Silva
Employees100
SectorHealthcare
IndustryBiotechnology
IPO Date2020-10-20
Dorfstrasse 29
Zug 6300
CH
41 415108022
About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Recent Insider Trades

NameTypeSharesPriceDate
Bodenstedt Matthias S-Sale 13,653 $20.02 2026-05-11
Bodenstedt Matthias S-Sale 2,426 $19.56 2026-04-14
Santos da Silva Jorg S-Sale 51,873 $18.23 2026-04-13
Santos da Silva Jorg S-Sale 98,127 $18.41 2026-04-10
Bodenstedt Matthias S-Sale 1,925 $19.51 2026-04-10

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms